Akero Therapeutics Inc (AKRO)

26.16 -0.45 (-1.69%) USD  |  NASDAQ  |  Jan 08, 16:00
26.15 -0.01 (-0.04%) After-Hours: 20:00
More

Akero Therapeutics SG&A Expense (Quarterly): 9.471M for Sept. 30, 2024

SG&A Expense (Quarterly) Chart

View SG&A Expense (Quarterly) for AKRO.
Upgrade now.
Sep '18
Jan '19
May '19
 
285.00
270.00
255.00
240.00
View SG&A Expense (Quarterly) Chart
Start Trial

Historical Data

View Historical Data
Start Trial

SG&A Expense Definition

View SG&A Expense Definition
Start Trial

SG&A expense (short for Selling, General and Administrative expense) is a line item on the income statement, though sometimes sales and marketing expenses are reported separately from general and administrative expenses.

Read full definition.

SG&A Expense (Quarterly) Range, Past 5 Years

View SG&A Expense (Quarterly) Range, Past 5 Years
Start Trial
--
Minimum
--
Maximum
--
Average
--
Median

SG&A Expense (Quarterly) Benchmarks

View SG&A Expense (Quarterly) Benchmarks
Start Trial
Madrigal Pharmaceuticals Inc 107.58M
89bio Inc 10.50M
NovaBay Pharmaceuticals Inc 2.65M
Palatin Technologies Inc 2.021M
iBio Inc 2.801M